<DOC>
	<DOCNO>NCT01827956</DOCNO>
	<brief_summary>Hypothesis : Cetuximab , anti-EGFR antibody , use radiotherapy treatment locally advance inoperable upper aerodigestive tract cancer . Actually , predictive biomarkers Cetuximab antitumor activity know setting . It show recently FCγRIIIA FCγRIIA receptor polymorphisms played role antitumor activity trastuzumab cetuximab . The investigator therefore hypothesize FCγRIIIA FCγRIIA receptor polymorphism may play predictive role Cetuximab effectiveness upper aerodigestive tract cancer recurrence metastatic disease make inaccessible loco regional treatment .</brief_summary>
	<brief_title>Role FCγRIIIA FCγRIIA Receptor Polymorphisms</brief_title>
	<detailed_description>Hypothesis : Cetuximab , anti-EGFR antibody , use radiotherapy treatment locally advance inoperable upper aerodigestive tract cancer . Actually , predictive biomarkers Cetuximab antitumor activity know setting . It show recently FCγRIIIA FCγRIIA receptor polymorphisms played role antitumor activity trastuzumab cetuximab . We therefore hypothesized FCγRIIIA FCγRIIA receptor polymorphism may play predictive role Cetuximab effectiveness upper aerodigestive tract cancer recurrence metastatic disease make inaccessible loco regional treatment . This study multicentre prospective pharmacogenetic observational study , conduct locally advanced inoperable upper aerodigestive tract cancer .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patient recurrent metastatic squamous cell carcinoma upper aerodigestive tract Patient locoregional extension readily treatable 18 year Follow participant center Patient information consent study participation Patient present multidisciplinary meeting ( RCP ) Aquitaine treatment contain cetuximab propose Belong social security system Pregnancy Patient psychological , social , family geographical reason , could treat monitor regularly study criterion , Patients deprive liberty guardianship could give consent study participation Inclusion another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Upper aero-digestive tract tumour</keyword>
	<keyword>FCGR3A FCGR2A receptor polymorphism</keyword>
	<keyword>Cetuximab efficacy</keyword>
</DOC>